Enterprise Value
-1.371M
Cash
23.31M
Avg Qtr Burn
-10.11M
Short % of Float
0.55%
Insider Ownership
2.67%
Institutional Own.
27.63%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tuspetinib mono/combo w/ Venetoclax Details Acute myeloid leukemia, Cancer, Leukemia, Relapsed/refractory acute myeloid leukemia | Phase 1/2 Data readout | |
Luxeptinib (CG-806) (BTK and FLT3 Inhibitor) Details Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Acute myeloid leukemia, Cancer | Phase 1/2 Update | |
APTO-253 (MYC inhibitor) Details Acute myeloid leukemia, Cancer, Myelodysplastic syndrome | Failed Discontinued | |
Tuspetinib (HM43239) & luxeptinib Details Acute myeloid leukemia, B-cell malignancies, Relapsed/refractory acute myeloid leukemia | Failed Discontinued |